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Abstract
Huntington’s disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by a trinucleotide (CAG)n
repeat expansion in the coding sequence of the huntingtin gene, and an expanded polyglutamine (.37Q) tract in the
protein. This results in misfolding and accumulation of huntingtin protein (htt), formation of neuronal intranuclear and
cytoplasmic inclusions, and neuronal dysfunction/degeneration. Single-chain Fv antibodies (scFvs), expressed as intrabodies
that bind htt and prevent aggregation, show promise as immunotherapeutics for HD. Intrastriatal delivery of anti-N-terminal
htt scFv-C4 using an adeno-associated virus vector (AAV2/1) significantly reduces the size and number of aggregates in
HDR6/1 transgenic mice; however, this protective effect diminishes with age and time after injection. We therefore explored
enhancing intrabody efficacy via fusions to heterologous functional domains. Proteins containing a PEST motif are often
targeted for proteasomal degradation and generally have a short half life. In ST14A cells, fusion of the C-terminal PEST
region of mouse ornithine decarboxylase (mODC) to scFv-C4 reduces htt exon 1 protein fragments with 72 glutamine
repeats (httex1-72Q) by ,80–90% when compared to scFv-C4 alone. Proteasomal targeting was verified by either
scrambling the mODC-PEST motif, or via proteasomal inhibition with epoxomicin. For these constructs, the proteasomal
degradation of the scFv intrabody proteins themselves was reduced,25% by the addition of the mODC-PEST motif, with or
without antigens. The remaining intrabody levels were amply sufficient to target N-terminal httex1-72Q protein fragment
turnover. Critically, scFv-C4-PEST prevents aggregation and toxicity of httex1-72Q fragments at significantly lower doses
than scFv-C4. Fusion of the mODC-PEST motif to intrabodies is a valuable general approach to specifically target toxic
antigens to the proteasome for degradation.
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Introduction
Huntington’s disease (HD) is the most prevalent of nine known
human neurodegenerative disorders linked to the expansion of
polyglutamine (polyQ) tracts in specific disease-associated proteins
[1]. The cellular localization of wild-type Huntingtin (htt) is
predominantly cytosolic and diffuse; however, N-terminal frag-
ments of mutant htt (mhtt) have been reported to form both
intranuclear and cytoplasmic inclusions in HD [2,3,4]. N-terminal
mhtt fragments can fold into several conformations resulting in
different solubilities and pathological consequences [5,6]. Al-
though the precise conformations of the toxic species are still a
matter of debate, it is clear that various misfolded N-terminal
cleavage products are a major early step in HD pathogenesis [7,8].
Because HD is a progressive genetic disorder with death occurring
10–20 years after diagnosis, early intervention therapies may
significantly improve patient quality of life by slowing and/or
reversing the course of the disease.
Intrabody-based therapies show significant potential for address-
ing the critical need to reduce the misfolded protein burden in HD
[9]. These recombinant single-chain and single-domain variable
fragments of full-length antibodies exhibit high specificity and
affinity for targets, can be selected, engineered, and delivered as
genes [10,11,12,13]. The N-terminal 17 amino acids of htt form a
highly conserved amphipathic alpha helix immediately preceding
the polyQ tract, and have been shown to be involved in membrane
binding, subcellular localization, aggregation, and toxicity
[14,15,16,17]. A naı ¨ve human spleen scFv phage-display library
screened against the N-terminal 17 amino acids of htt generated the
scFv-C4 intrabody, which successfully counteracts in situ length-
dependent htt aggregation, in both cell culture [18,19,20,21] and
Drosophila models of HD [22]. scFv-C4 preferentially binds to
soluble mhtt N-terminal fragments. It is only weakly active against
endogenous full-length mhtt and wild type htt, possibly due to
epitope inaccessibility [20]. Intrastriatal delivery of scFv-C4, using
the adeno-associated virus vector (AAV2/1), resulted in a significant
reduction in the size and number of mhtt aggregates in B6.Cg-
HDR6/1 transgenic mice. However, the neuroprotective effect
weakened both with severity of disease at time of injection, and with
age beyond 6 months, although it does not disappear entirely [23].
Additional optimization of scFv-C4 is required for this intrabody to
be of future use in clinical applications.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29199In this study, we developed a bifunctional intrabody that
prevented N-terminal htt exon 1 (httex1) protein fragments from
aggregating while directing them to the proteasome for degrada-
tion. Proteins that contain enriched regions of amino acids Proline
(P), Glutamic Acid (E) or Aspartic Acid (D), Serine (S), and
Threonine (T), otherwise known as PEST regions, are targeted for
proteasomal degradation and generally have a short half-life.
Mouse Ornithine Decarboxylase (mODC), a cytosolic enzyme
involved in the biosynthesis of polyamines, is rapidly degraded in
mammalian cells [24]. Deletion of the C-terminal PEST motif
from mODC stabilizes mODC independent of protein synthesis,
with no detrimental effects on enzyme activity [24]. Transfer of
the mODC-PEST motif (amino-acids 422–461) to the C-terminus
of stable proteins such as green fluorescent protein [25] and
Luciferase [26] significantly reduced their intracellular half-life.
Although there is one report in the literature that a PEST-fused
intrabody against b-galactosidase was unsuccessful in depleting its
target, intrabodies and targets can vary greatly in their
intracellular properties, and our system differs significantly from
the one reported [27]. We have previously shown that fusion of a
nuclear localization sequence (NLS) derived from SV40 Large T
antigen to scFv-C4 was able to bind, transport, and sequester
soluble httex1 protein fragments with 72 glutamine repeats fused
to enhanced green florescent protein (httex1-72Q-GFP) into the
nuclei [18,19]. Based on the ability of the scFv-C4-NLS fusion
construct to redirect httex1-72Q-GFP protein to different
subcellular compartments, we hypothesized that fusion of the
proteolytic PEST signal sequence of mODC to scFv-C4 could
affect the steady-state level of httex1-72Q-GFP by redirecting the
antigen-antibody complex to the proteasome. Our current studies
provide a strong proof of concept that PEST fusion can greatly
enhance the functionality of our intrabody, with implications for
multiple additional diseases.
Results
Anti-htt scFv-C4-PEST intrabody enhances degradation
of httex1-72Q fragments
Our approach sought to harness the proteasomal machinery for
the targeted degradation of httex1 protein fragments. To develop a
bifunctional intrabody that redirected httex1 protein fragments to
the proteasome for degradation, while preventing aggregation of
mhtt, we fused the mODC-PEST motif (amino-acids 422–461) to
the C-terminus of scFv-C4 intrabody to generate scFv-C4-PEST.
Because the targeted epitope of scFv-C4 is the N-terminal 17
amino acids of htt, scFv-C4 and scFv-C4-PEST are likely to bind a
variety of N-terminal mhtt fragments produced from the cleavage
of full-length mhtt during HD pathology. We co-transfected
intrabody constructs (empty vector, scFv-C4, and scFv-C4-PEST)
with GFP-labeled huntingtin fragments of either non-pathological
(httex1-25Q-GFP) or pathological (httex1-72Q-GFP) repeat
lengths to determine if scFv-C4-PEST could redirect N-terminal
htt fragments to the proteasome in ST14A striatal progenitor cells
[28].
Live cell imaging of transfected cells (Fig. 1A) revealed that
without intrabody, httex1-25Q-GFP remained diffuse throughout
the cell compared to httex1-72Q-GFP, which formed punctate
aggregates. In cells co-transfected with scFv-C4 and httex1-72Q-
GFP, GFP-labeled mhtt was diffusely localized throughout the cell,
as previously reported [20,21,29,30]. However, co-transfection of
scFv-C4-PEST resulted in a dramatic reduction of observable
httex1-25-QGFP and httex1-72Q-GFP fluorescence (Fig. 1A).
Residual httex1-72Q-GFP seen after 4-fold overexposure of scFv-
C4-PEST showed a phenotype consistent with native scFv-C4
(Data not shown). In agreement with live cell imaging, scFv-C4-
PEST vs. scFv-C4 showed a 51% reduction of monomeric htt in
httex1-25Q-GFP and a 78% reduction of httex1-72Q-GFP co-
transfected cells by Western blot (Fig. 1B). To assess the
effectiveness of our anti-htt intrabody based therapy on the
biochemical formation of mhtt aggregates, we used agarose gel
electrophoresis for resolving aggregates (AGERA). Unlike sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
where aggregated mhtt is trapped in the stacking gel, AGERA
allows aggregated mhtt to be separated based on size, with larger
aggregates remaining near the top of the gel [31]. In cells co-
transfected with empty vector and httex1-72Q-GFP, there was a
large smear of aggregated mhtt compared to cells co-transfected
with scFv-C4; however, in cells co-transfected with scFv-C4-PEST
aggregated htt was substantially reduced with respect to empty
vector and scFv-C4 transfected cells (Fig. 1C, right panel). scFv-
C4-PEST appeared to remove httex1-25Q-GFP as well, but
presumably at the level of monomer (Fig. 1C, left panel).
scFv-C4-PEST inhibits polyQ-mediated toxicity of mutant
httex1-72Q-GFP protein fragments
To further examine functionality, viability was assayed by flow
cytometric analysis with propidium iodide (PI). As seen in previous
studies, we observed an increase of PI-positive non-viable cells
when empty vector was co-transfected with httex1-72Q-GFP
compared to cells co-transfected with httex1-25Q-GFP (Fig. 2A)
[18]. Both scFv-C4 and scFv-C4-PEST inhibited polyQ-mediated
toxicity of mutant httex1-72Q-GFP protein fragments (Fig. 2A). In
agreement with findings reported in Figure 1, scFv-C4-PEST
significantly reduced the geometric mean fluorescence intensity
(MFI) of GFP labeled httex1-25Q and httex1-72Q cells by 1.5 and
1.8-fold, respectively (Fig. 2B).
PEST scramble and specific inhibition of the proteasome
eliminates the enhanced degradation of N-terminal
httex1-72Q-GFP protein fragments
The solubility of human scFv intrabodies can be improved by
an overall negative charge at cytoplasmic pH and increased
hydrophilicity (as demonstrated by decreased grand average of
hydropathicity, GRAVY score) [32]. Our previous data show that
addition of a highly charged acidic 36FLAG tag to aggregation-
prone positively charged intrabodies resulted in increased
intracellular solubility [32]. Because a PEST sequence is defined
by hydrophilic stretches of amino acids greater than or equal to 12
residues in length [33], addition of a PEST motif to scFv
intrabodies may enhance their intracellular solubility. Sequence
analyses of scFv-C4 and estimation of net charge at pH 7.4
GRAVY hydrophilicity score predicted that fusion of hydrophilic
PEST motif to scFv-C4 could increase solubility (Table 1). To
determine if the enhanced clearance of httex1-72Q-GFP protein
fragments was simply due to enhanced solubility of scFv-C4, we
scrambled the PEST motif (scFv-C4-PEST-SCR), while main-
taining the physico-chemical properties of scFv-C4. Because
positively charged residues are not contained within PEST regions
[33], we rearranged the PEST motif placing positively charged
amino acids within the PEST motif. The subsequent PEST-FIND
scores for scFv-C4-PEST and scFv-C4-PEST-Scramble were
+5.16 and 22.41 respectively (Table 1).
To determine if the enhanced clearance of httex1-72Q-GFP
protein fragments was due to enhanced scFv-C4-PEST intrabody
protein solubility, we examined protein levels of the different
intrabody constructs. There appears to be no qualitative difference
in the solubility of HA tagged scFv-C4, scFv-C4-PEST, or scFv-
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into detergent-soluble and –insoluble cell lysates (Fig. 3B). These
data suggest that enhanced solubility of scFv-C4-PEST is not a
major factor in PEST-mediated enhanced target clearance.
Live cell imaging of scFv-C4-PEST-SCR produced similar
results to scFv-C4 for inhibiting aggregation of httex1-72Q-GFP
(Fig. 3A). In agreement with findings reported in Figure 1,
monomeric mhtt was significantly reduced in empty vector control
and scFv-C4-PEST detergent-soluble fractions (Fig. 3B). As
expected, the levels of monomeric mhtt were similar between
scFv-C4 and scFv-C4-PEST-SCR (Fig. 3B). The absence of
monomeric mhtt from the insoluble fractions is due to aggregation
of httex1-72Q-GFP, which is retained in the stacking gel. To
address this issue, total cell lysates were analyzed by AGERA.
Empty vector and httex1-72GFP co-transfected cells contain a
substantial amount of detergent insoluble mhtt compared to all
other groups (Fig. 3C, Left lane). As expected the levels of
detergent insoluble mhtt are similar between scFv-C4-PEST-SCR
and scFv-C4 compared to scFv-C4-PEST co-transfected cell
lysates (Fig. 3C). Immunoblot quantification of this series showed
Figure 1. scFv-C4-PEST enhances degradation of GFP-tagged httex1 soluble and insoluble protein fragments. ST14A cells were co-
transfected with GFP-tagged httex1-25Q (httex1-25Q-GFP) or (httex1-72Q-GFP), plus either empty vector, scFv-C4, or scFv-C4-PEST plasmids. A.
Representative live cell imaging depicting reduction of httex1-72Q-GFP and httex1-25Q-GFP fluorescence in the scFv-C4-PEST co-transfected groups.
Phase contrast confirms uniform cell integrity. 48 h; bar=20 mm. B. SDS-PAGE Western blot and densitometry probed for htt (EM48), quantified vs.
actin. Monomeric soluble mhttex1 protein fragments were quantitatively reduced in scFv-C4-PEST vs. scFv-C4 co-transfected cells. (Mean 6 SEM;
*p,0.05 comparing httex1-25Q-GFP co-transfections; *p,0.05 comparing httex1-72Q-GFP co-transfections) Note that B shows only soluble httex1-
72Q fragment levels, which are low unless intrabody is present. C. Agarose Gel Electrophoresis for Resolving Aggregates (AGERA) shows the decrease
of detergent-insoluble material in httex1-72Q-GFP to scFv-C4-PEST co-transfected cells compared to other groups.
doi:10.1371/journal.pone.0029199.g001
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cells compared to scFv-C4 and scFv-C4-PEST-SCR (Fig. 3D).
To further confirm that scFv-C4-PEST is acting in a
proteasome-dependent manner, we treated cells with epoxomicin,
a potent and selective proteasome inhibitor [34]. ST14A cells were
co-transfected with httex1-72Q-GFP and scFv-C4-PEST. 36 h
after transfection, cells were treated with 10 mM epoxomicin or
vehicle control DMSO, and then harvested at 48 h. As expected,
12-h proteasome inhibition with epoxomicin resulted in reduced
clearance of insoluble mhtt in scFv-C4-PEST and httex1-72Q co-
transfected cells (Fig. 3E).
PEST fusion reduces steady-state scFv-C4 intrabody
levels modestly, and independent of antigen
Sibler et al. reported that fusion of the mODC-PEST motif to
the anti- b-galactosidase scFv-13R4 intrabody resulted in a
destabilization of the intrabody-PEST construct in the absence
of intracellular target [27]. The experiments above also allowed us
to determine if fusion of the mODC-PEST motif to the C-
terminus altered the steady state levels of anti-htt scFv-C4. In
Fig. 4, we quantitatively compared the expression levels of scFv-
C4 and scFv-C4-PEST with and without intracellular target
httex1-72Q-GFP, using a hemagglutinin (HA) tag to identify the
intrabodies. In contrast to scFv-13R4-PEST intrabody, our steady-
state protein levels of scFv-C4-PEST were reduced by only 25%
independent of antigen presence or absence. Likewise, the levels of
a second intrabody, anti-fibrillar scFv-6E and scFv-6E-PEST are
similar with and without intracellular target httex1-72Q-GFP
(Fig. 5B). Interestingly, scFv-13R4, scFv-C4 and scFv-6E were
derived from different intrabody libraries. These data suggest that
not all classes of intrabodies are significantly destabilized by the
addition of the mODC-PEST motif.
PEST mediated degragation of mhtt is specific to soluble
monomeric, and not fibrillar, species
Insoluble polyQ protein aggregates are generally resistant to
proteolytic degradation [35]. We fused the mODC-PEST motif to
a fibril-specific scFv-6E intrabody [36], which does not bind to the
soluble monomeric mhtt fragment [18], to investigate whether an
aggregated/fibrillar htt-PEST complex is also resistant to
proteolytic degradation. Previously, we reported that under
slightly different conditions, scFv-6E modestly enhanced the
aggregation propensity of httex1-72Q-GFP compared to httex1-
25Q-GFP in ST14A cells [18]. As opposed to the soluble
monomer binding scFv-C4 intrabody studies above, live cell
imaging of httex1-72Q-GFP is qualitatively indistinguishable when
PEST is fused to the anti-fibrillar scFv-6E intrabody (Fig. 5A).
Western blotting confirmed that the levels of monomeric mhtt
were comparable among empty vector, scFv-6E, and scFv-6E-
PEST (Fig. 5B). Detergent-insoluble migration patterns of httex1-
72Q-GFP resolved by AGERA were also similar between empty
vector, scFv-6E, and 6E-PEST through the gel (Fig. 5C). These
Figure 2. scFv-C4-PEST further enhances viability in ST14A co-transfection experiments compared to scFv-C4. Viability and GFP
geometric mean fluorescent intensity (MFI) were assayed by flow cytometric analysis 48 h after transfection. For scFv-C4-PEST vs.scFv-C4: A. The
percentage of propidium iodide (PI) positive nonviable cells is reduced. B. Total httex1-25Q-GFP and httex1-72Q-GFP reduction was confirmed.
(means 6 SEM; *** p,0.001 within groups.)
doi:10.1371/journal.pone.0029199.g002
Table 1. Physico-chemical properties of scFv-C4 intrabodies.
Isoelectric point Net Charge at pH 7.4 Gravy Score PEST Find Score
scFv-C4 6.62 20.5 20.282 ------
scFv-C4-PEST 5.24 25.5 20.328 5.16
scFv-C4-PEST-SCR 5.24 25.5 20.328 22.41
Physico-chemical determinants of soluble intrabody expression. Solubility is improved by an overall negative charge at pH 7.4 and reduced GRAVY score. The GRAVY
score is the average hydropathy score for all the amino acids in the protein, with a more negative score indicating increased hydrophilicity. The PEST-FIND program
http://emboss.bioinformatics.nl/cgi-bin/emboss/pestfind objectively produces a score ranging from about 250 to +50. A score above +5 denotes a PEST region
[33].
doi:10.1371/journal.pone.0029199.t001
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htt is inefficiently degraded by the proteasome [37].
scFv-C4-PEST alters target at a lower dose than scFv-C4
A therapeutic range is especially advantageous for gene therapy.
We therefore co-transfected ST14A cells with a 1:2 or a 1:5 ratio
of intrabody to httex1-72Q-GFP. In contrast to previous
experiments (see Fig. 1A), where intrabody and httex1-72Q-GFP
were co-transfected at a 1:1 ratio, aggregation of httex1-72Q-GFP
was present in scFv-C4 transfected cells at a 1:2 ratio and was
noticeably elevated at a 1:5 ratio (Fig. 6A). However, scFv-C4-
PEST transfected cells still enhanced the clearance of httex1-72Q-
GFP at a 1:2 ratio of intrabody to httex1-72Q-GFP. At a 1:5 ratio
of scFv-C4-PEST to httex1-72Q-GFP, scFv-C4-PEST maintained
httex1-72Q-GFP in a mostly non-aggregated soluble state
(Fig. 6A). Western blots of the dose response experiments
confirmed the live cell observation that scFv-C4-PEST can
counteract aggregation very effectively at 1:2, and still shows
effects at 1:5 (Fig. 6B). Compared to scFv-C4, the levels of
insoluble httex1-72Q-GFP were reduced at 1:2 and 1:5 ratio of
scFv-C4-PEST to httex1-72Q-GFP (Fig. 6C).
Discussion
In HD, the initial pathogenic trigger is the misfolding of mhtt,
which eventually leads to intracellular accumulation of a toxic N-
terminal fragment of the mhtt protein with excess polyQ.
Prevention of mhtt misfolding, or reducing its availability for
abnormal intracellular interactions, should therefore offer signif-
icant protection. We and others have developed intrabodies that
bind to the regions adjacent to the polyQ repeat [38,39,40],
altered the protein context, and reduced the aggregation and
toxicity of mhtt. One very promising candidate, the scFv intrabody
scFv-C4, targets the N-terminal 17 amino acids of the htt protein,
a domain of htt protein that is increasingly being recognized as
pivotal in mediating physiological and pathological pathways in
HD [41]. The human scFv-C4 is very effective at counteracting
the misfolding and toxicity of mutant httex1 in transient
transfection assays of multiple cell lines [10] and stressed
organotypic brain slice cultures [21]. In an HD Drosophila model,
the intrabody shows strong protective effects initially, and
increases lifespan by 30%, although the mutant flies still die
prematurely [42]. AAV2/1 delivery of this intrabody to the
striatum of inbred B6.HDR6/1 mice also demonstrates pheno-
typic correction at the cellular level; however, scFv-C4 alone has
been insufficient to produce amelioration of the full disease
phenotype over a period of several months [23]. This could be due
to targeting of a suboptimal epitope, gradual dilution of efficacy
due to build-up of mhtt that escapes intrabody binding, and/or
insufficient delivery of an otherwise effective reagent. Work here
and elsewhere suggests that all three of these parameters impact
long-term efficacy in vivo. Here, we addressed the first two factors
by engineering fusions of scFv-C4 to heterologous proteolytic
domains that can lead to rapid and irreversible turnover of the
antigen-antibody complex. Inducing rapid turnover of the bound
antigen reduces dependence on the precise functionality of the
bound epitope, although the epitope must still be available. We
show that fusion of scFv-C4 to a proteasomal PEST signal domain
results in greatly enhanced degradation of soluble mutant httex1
protein fragments in a transiently-transfected striatal cell line. This
in turn reduces both the aggregate burden and the toxicity of the
mutant protein.
The goal of this study was to determine whether a bifunctional
intrabody could manipulate the stability of its intracellular target.
Because heterologous transfer of the mODC-PEST motif to the C-
terminus of stable proteins significantly reduced their intracellular
half-life [25,26], fusion of a PEST motif to scFv-C4 might
destabilize the intrabody protein itself, thus reducing the amount
of intrabody available to bind to its target. For this reason, we
chose a specific mODC-PEST sequence that was known to induce
Figure 4. PEST fusion reduces steady-state scFv-C4 intrabody
levels modestly, and independent of antigen. Using dual
transfections as above, scFv-HA levels were compared among scFv-
C4, scFv-C4-PEST, and scFv-C4-PEST-SCR, in the presence and absence
of httex1-72Q-GFP. Levels of scFv-C4-PEST were reduced by ,25%
when compared with scFv-C4 or the scrambled (inactive) PEST. The
presence or absence of antigen had no significant effect on intrabody-
PEST levels. (n=4; mean 6 SEM; *p,0.05. for C4 vs. C4-PEST/C4-PEST-
SCR.)
doi:10.1371/journal.pone.0029199.g004
Figure 3. Scrambling the PEST sequence and specific inhibition of the proteasome eliminates the enhanced degradation of httex1-
72Q-GFP. A. Representative live cell images of dual transfections. Diffuse httex1-72Q-GFP fluorescence is similar between scFv-C4-PEST-SCR and
scFv-C4 cells, and much higher than scFv-C4-PEST. B. Biochemical fractionation of HA-tagged fluorobodies from ST14A cells. Detergent-soluble and -
insoluble cell lysates were prepared as described in Materials and Methods. Empty vector and scFv-C4-PEST transfected cells express minimal levels of
monomeric htt, while scFv-C4-PEST-SCR and scFv-C4 transfected cells have similar levels of monmeric htt C. AGERA. There is an increase of detergent-
insoluble material in scFv-C4-PEST-SCR transfected cells compared to scFv-C4-PEST. D. Western blotting of total protein. Monomeric mhtt levels do
not differ between scFv-C4 and scFv-C4-PEST-SCR co-transfected cells. C4-PEST reduces soluble mhtt by ,90%, and empty vector control mhtt is
insoluble E. Proteasome inhibition reduced clearance of insoluble httex1-72Q by scFv-C4-PEST. ST14A cells were co-transfected with httex1-72Q-GFP
and scFv-C4-PEST. 36 h after transfection, cells were treated with 10 mM epoxomicin (+), a potent and selective proteasome inhibitor [34]; or DMSO
vehicle control. Insoluble mhtt was assessed at 48 h using AGERA. Proteasome inhibition resulted in reduced clearance of htt exon1 protein
fragments by scFv-C4-PEST.
doi:10.1371/journal.pone.0029199.g003
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GFP-PEST studies [25]. It was also important to consider the
functional state of the proteasome in affected cells. The ubiquitin-
proteasome system (UPS) has been implicated in the failure to
degrade mhtt, leading to aggregate formation [43]. Proteasome
impairment is thought to occur through sequestering of 20S
proteasome subunits [37], failure of aggregated mhtt to enter the
20S proteasome core [44], or clogging of the proteasome with
polyglutamine fragments [45]. Fortunately, in vivo studies have
shown that 26S proteasome is not impaired in HDR6/2 mice [44],
and it is the 26S proteasome that recognizes the PEST motif of
mODC and processes it for degradation [46]. Therefore, our
strategy was designed to take advantage of this conserved
functionality.
The difference in the ratios of scFv-C4 to scFv-C4-PEST
intrabody levels vs. httex1-72Q-GFP+scFv-C4 to httex1-72Q-
GFP+scFv-C4-PEST was larger than expected. Our data suggest
that this particular combination of intrabody and PEST does not
lead to rapid degradation of the unliganded intrabody fused to
PEST. With intrabody binding, the mhtt antigen appears to be
delivered to the proteasome and degraded, while sufficient
intrabody-PEST protein remains available for additional substrate.
Qualitative comparisons of cellular protein levels of a second
intrabody, scFv-6E, which binds only to aggregated fibrillar
httex1, also show intrabody levels that appear even less reduced by
fusion with this PEST motif. However, in this case the fibrillar
antigen-antibody complex could not be degraded by the protea-
some, which is in agreement with data suggesting that once htt has
aggregated it is resistant to degradation by the UPS [35].
Published results suggest that these types of highly structured
aggregates are degraded via autophagy [43,47].
For safety reasons, it would be valuable to use an intrabody that
preferentially targets N-terminal mhtt fragments, because long-
term reduction of full-length wild-type htt may exacerbate
neurological degeneration, even in the presence of low levels of
mhtt [48] We have previously shown that scFv-C4 preferentially
Figure 5. Fusion of PEST motif to anti htt fibril-specific scFv-6E intrabody does not degrade htt fragments in ST14A cells. ST14A cells
co-transfected with httex1-72Q-GFP and either empty vector, scFv-6E, or scFv-6E-PEST plasmids. Cells imaged and processed at 48 h. A. Live cell
imaging. scFv-6E-PEST does not appear to alter the aggregation of htt compared to empty vector or scFv-6E. B. Western blotting. Monomeric htt is
similar between groups. HA-tagged intrabody levels are similar between groups. C. Detergent-insoluble material resolved by AGERA is similar
between empty vector and 6E-PEST groups.
doi:10.1371/journal.pone.0029199.g005
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active against endogenous full-length mhtt and wild type htt,
possibly due to epitope inaccessibility [20]. Pilot experiments using
the scFv-C4-PEST construct in B6.Cg-R6/1 HD and wild-type
mouse striatum have not shown excess transgene-induced toxicity
up to 6 months after injection of AAV2/1-scFv-C4-PEST (data
not shown). However, quantitation of the level of residual wild-
type full-length htt will be necessary prior to extending these
studies to clinical use.
An additional safety/efficacy issue for bifunctional intrabodies is
subcellular localization. Soluble mhtt appears to be largely
cytoplasmic, while aggregated mhtt is often found juxtaposed to
the nucleus in ST14A cells [18]. In contrast to in situ studies of N-
terminal mhttex1 fragment localization, aggregated mhtt is
primarily localized in the nucleus of B6.Cg-R6/1 HD transgenic
mice. Localization of htt is thought to be due primarily to a motif
within the AA1–17 region that acts as a cytoplasmic retention
signal [15,17,49,50,51]. Intrabodies that bind AA1–17 might
influence this distribution by masking nuclear export or cytoplas-
mic retention signals, thereby increasing nuclear concentrations
and toxicity. scFv-C4, which was selected against AA1–17,
appears to bind to the far N-terminus, AAs 2–12 (Thumfort and
Ingram, pers. Comm.). scFv-C4 does not lead to nuclear
concentration of diffuse httex1-72Q-GFP, as shown here and in
our previous studies. Another engineered intrabody, VL12.3, was
selected against a peptide that included AAs1–20 [29,30], and the
epitope has recently been identified as including AAs 5–18 [52].
This binding therefore is likely to block the phosphorylation at
serine 13 and serine 16, which fits well with in situ and in vivo
observations that the VL12.3-mhttex1 fragment complex is
preferentially found in the nuclear compartment, and may not
be protective in vivo reviewed in Butler et al 2011 [9]. It would be
interesting to test whether a PEST fusion of this intrabody can
utilize nuclear proteasomes for mhtt degradation.
We were able to confirm that N-terminal mutant httex1
fragment degradation is dependent upon proteasomal function,
since epoxomicin, a potent and selective proteasome inhibitor
[34], inhibited the turnover. The intrabody-PEST mediated
Figure 6. Targeted degradation of htt occurs in a dose-dependent manner. ST14A cells co-transfected with 1:2 or 1:5 transfection ratio of
intrabody-PEST to httex1-72Q-GFP plasmids. A. Live cell imaging. Httex1-72Q is diffuse at 1:2, and being begins to form aggregates at a 1:5
transfection ratio of intrabody to httex1-72Q-GFP in scFv-C4 transfected cells. Fusion scFv-C4-PEST clears mhtt at 1:2, and keeps mhtt diffuse at 1:5. B,
C. Western blots of EM48 immunoreactivity measuring the soluble (B; SDS-PAGE) and insoluble (C; AGERA) material to confirm live cell imaging.
doi:10.1371/journal.pone.0029199.g006
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order of key amino acids within mODC-PEST motif rather than
enhanced solubility. The intracellular stability of scFv-intrabodies
is notoriously poor due to macromolecular crowding and an
unfavorable redox potential within the cellular cytoplasm
[10,29,53]. We have previously reported that cis-acidification of
a poorly soluble scFv-intrabody with a C-terminal 3X-Flag tag can
enhance intrabody solubility and function [32], thus it is possible
that the addition of this highly acidic domain would improve the
scFv-C4 intrabody function via enhanced folding effects. However,
a scrambled version of the PEST used here maintained the charge
density without enhancing the intrabody-mediated turnover of its
target. Since both scFv-C4 and scFv-6E are soluble in the cellular
environment, it is unlikely that enhanced solubility contributed to
the clearance of htt fragments.
Intrabody-mediated degradation with a PEST motif had been
previously tested with a fusion intrabody scFv-13R4 against b-
galactosidase [27]. In that case, PEST fusion rendered the
intrabody-PEST protein itself unstable, and binding to its target
stabilized the complex. The (b-gal) target protein is extremely
large, which may account for the inability of cellular proteasomes
to degrade the antigen-antibody complex. The scFv-13R4 intra-
body itself also belongs to a different framework family than scFv-
C4 [54]. The scFv-C4 intrabody was selected from a natural non-
immune human library [55], while scFv-6E used a consensus
framework [56,57]. The biophysical and intracellular properties of
intrabodies are quite dependent upon both the frameworks and
the complementary determining regions. This should carry over to
the properties of the fusion intrabodies as well. We have previously
reported that the anti-b-gal scFv-13R4 parent intrabody also
differs from anti-htt scFv-C4 in solubility calculations [32]. In an
attempt to circumvent the potential effect of a proteasomal
targeting signal on steady-state intrabody levels, Mechionna and
Cattaneo created inducible suicide intrabodies by fusion with
IkBa, which must be activated by TNFa [58]. After activation,
scFv-R4-IkBa reduced b-gal by 15–20%, while an anti-Tau
scFv#2 reduced t151–422 by 70–90%. However, as noted in their
publication, the requirement to use a biologically active ligand is
suboptimal, due to potential side-effects. It is clear from our work
that there may be many classes of intrabodies that do not require
exogenous activation in order to effectively degrade targets.
Testing of constitutively active intrabody fusions is quite
straightforward, allowing empirical determination of the most
suitable fusions of intrabodies and PEST domains for specific
targets. Once a sufficient number of studies have been performed
on diverse constructs, it may also be possible to predict the
behavior of fusions and engineer them to degrade targets without
suicide. Fusion construct approaches should empower long-term
intrabody-mediated correction, and may be more generally
applicable to intrabody therapeutics of neurological diseases
characterized by abnormal protein accumulation.
Materials and Methods
Expression plasmids
cDNA, previously described by Kvam et. al., [18] encoding scFv-C4
(GenBank accession number EU490426) was PCR amplified using
complementary primers. The forward primer (59-TGCTCTA-
GACGCCATGGCCCAGGTG CAGC-39) introduced an XbaI
restriction site (underlined) prior to the existing 59 Kozak sequence.
The reverse primers (Standard: 59-CCCAAGCTTTTACTACA-
CATTG ATCCTAGCAGAAG CACAGGCTGCAGGGTGACG-
GTCCATCCCGCTCTCCTGGGCACAAGACATGGGCAGC-
GTGCCATCATCCTGCTCCTCCACCTCCGGCGGGAAGC-
CATGGCTCGCGTAGTCTGGGACGTCG-39;‘ ‘ S c r a m b l e ’ ’ :5 9-
CCCAAGCTTTTACTACAGCCTGTGACGATGCACTGCA-
GACATAGGGGCAGCAGAGTCCCCGCTCTGGATATTGG-
CCTCACAAGCCATGGGCGTACAGAACTCATCCTCGCCA-
TCCTCCACCGGCTGC GGGCTGCCCGCGTAGTCTGGGA-
CGTCG-39) introduced a standard or scrambled PEST motif
corresponding to amino acids 422–461 from mouse ornithine
decarboxylase (GenBank accession number NM_013614.2) and a
HindIII (BOLD) restriction site immediately following the stop codon.
The resulting PCR product was ligated into pAAV-MCS (Stratagene)
at the corresponding Xba1 and HindIII restriction sites using standard
cloning techniques. scFv-6E (GenBank accession number FJ695518)
was cloned into pAAV-MCS in a similar manner. To create
fluorescently-labeled intrabodies, scFv-C4 -HA-PEST was PCR
amplified using a complementary forward primer (59-TGCTCTA-
GACGCCATGGCCCAGG-39) and a reverse primer that introduced
a BamHI (underlined) restriction site (59-CGGGATCCCACATT-
GATCCT AGCAGAAGCAC-39). The PCR removes the stop codon,
allowing the scFv-C4 -HA-PEST construct to be ligated in-frame 59 to
a( G l y 4Ser)4 flexible peptide repeat linked to a humanized enhanced
green fluorescent protein (EGFP), all on a pcDNA3.1(-) plasmid
backbone previously described by Kvam et al. [18]. The resulting
expression plasmid cassette was the following: Kozak sequence-scFv-
C4-HA-PEST-(Gly4Ser)4-EGFP-stop. Vectors for the expression of
human httex1 with different polyglutamine repeat lengths labeled with
either EGFP or RFP respectively, were described elsewhere
(pcDNA3.1-Httex1-25Q-EGFP, pcDNA3.1-Httex1-72Q-EGFP [59],
and pcDNA3.1-Httex1-25Q-RFP, pcDNA3.1-Httex1-72Q-RFP [60].
All expression plasmids were prepared using EndoFree Plasmid Maxi
(Qiagen) and confirmed by DNA sequencing.
Cell culture and transfection
Undifferentiated ST14A cells were cultured according to
standard protocols [28]. ST14A cells were transiently transfected
with jetPEI DNA transfection reagent (Polyplus Transfection Inc.)
as previously described [18]. For all transfections, intra-
body plasmids were applied at equal (1:1) or lesser ratios (1:2 or
1:5) to httex1 plasmids, and cells were analyzed 48 hours
post-transfection.
Cell fractionation, AGERA, and Western blot
Transiently transfected ST14A cells were collected from 6-well
culture dishes by trypsinization and washed twice with PBS.
Soluble and insoluble protein fractions were isolated as previously
described [18]. Briefly, whole-cell lysates were extracted at 4uCi n
50 uL/well of RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS)
supplemented with complete protease inhibitor cocktail (Roche).
Detergent-insoluble material was pelleted by microcentrifugation
(13,000 rpm 610 min., 4uC). Soluble protein in the supernatant
was quantified using Bio-Rad DC Protein Assay kit (Bio-Rad
Laboratories). Lysates were adjusted to 1 mg/mL in 2X
denaturing sample buffer (125 mM Tris, 4% SDS, 20% glycerol,
10% 2-mercaptoethanol, 0.02% bromophenol blue, pH 6.8) and
boiled. Insoluble pellet fractions were washed with RIPA,
resuspended in 50 mL/well of 2X denaturing sample buffer, and
boiled for 15 min. Equal volumes of pellet and soluble frac-
tions corresponding to, 20 mg of total protein (10 mL) were
resolved by SDS-PAGE and transferred onto PVDF membranes
(PerkinElmer).
Aggregated huntingtin was quantified by agarose gel electro-
phoresis for resolving aggregates (AGERA) method [31]. Briefly,
samples were homogenized in 10 volumes (w/v) tris-saline (10 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 2% SDS) and complete
Proteasome-Directed Intrabodies
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1.5% agarose gels, 1.5 g agarose (Invitrogen) was dissolved in
100 mL 375 mmol/L Tris-HCl, pH 8.8 and then boiled. After
melting, SDS was added to a final concentration of 0.1% (w/v).
Samples were diluted 1:1 into 2X non-denaturing sample buffer
(150 mmol/L Tris-HCl pH 6.8, 33% glycerol, 1.2% SDS and
bromophenol blue) and incubated for 5 min. at 95uC. Forty mgo f
protein was loaded per AGERA lane. After loading, gels were run
in Laemmli running buffer (192 mmol/L glycine, 25 mmol/L
Tris-base, 0.1% (w/v) SDS) at 100 V, 2 A until the bromophenol
blue running front reached the bottom of the gel. A Transblot SD
semi-dry electroblotter (BIORAD) was used to blot the gels on
PDVF membranes (Millipore) at 200 mA for 1 hour. Membranes
were then developed using mouse monoclonal EM48 (1:1000,
Chemicon). HA-tagged intrabodies and endogenous actin were
probed with monoclonal anti-HA (1:5,000, Covance) and anti-
actin (1:1000, Sigma) Abs, respectively, labeled with HRP-
conjugated goat-anti-mouse IgG (1:2000, Santa Cruz), and
detected by ECL (PerkinElmer).
Live-cell imaging and aggregation counts
ST14A cells transfected with GFP- and/or mRFP-tagged reporters
were imaged directly in 6-well culture dishes using an Olympus IX70
inverted microscope equipped with an Olympus IXFLA Inverted
Reflected Light Fluorescence Observation attachment and RGB
Mirror Cube filter wheel (Olympus). Cells were observed without
fixation using a 406lens, and images were captured 48 hours post-
transfection with a SPOT RT Color CCD camera using SPOT
Advanced software (Diagnostic Instruments). Digital images were
overlayed and cropped using Adobe Photoshop.
Flow cytometry
ST14A cells were seeded into 6-well culture dishes (2.50610
5
cells/well) and transfected, 24 hours later, in triplicate wells, with
plasmids encoding GFP (containing either normal or expanded
polyglutamine repeat tracts) and either intrabody or empty vector.
Approximately 48 hours post-transfection, cell medium was
harvested and adherent cells were collected by trypsinization.
Harvested cells and exhausted media were combined and passed
through a 70 mm cell strainer (BD Biosciences). Cells were pelleted
by centrifugation (800 rpm, 5 min.) and resuspended in 1 mL of
FACS buffer (16 Ca2
+- and Mg2
+-free PBS, 10% FBS) containing
50 mM propidium iodide (PI; Sigma). Cells were stained for
20 min. in the dark and pelleted by centrifugation (4,000 rpm,
5 min.). Cell pellets were resuspended in 0.5 mL of FACS buffer/
well and transferred to Falcon 5 mL round-bottom polystyrene
FACS tubes. Labeled cells were sorted by fluorescence using a BD
FACSCalibur Flow Cytometer (BD Biosciences) and a minimum of
30,000 events were recorded per sample using BD CellQuest Pro
software. GFP was detected with an FL1 detector, and PI with FL3.
Prior to each experiment, the flow cytometer was calibrated against
three control groups: (1) unstained ST14A cells to gate autofluo-
rescence, (2) unstained ST14A cells expressing httex1-25Q-eGFP
alone to identify transfected cells, and (3) stained ST14A cells pre-
treated with H2O2 for maximal PI uptake. Using BD CellQuest Pro
software, data were displayed in two-color dotplot formats on a log-
scale, and cell death was expressed as a percentage by dividing the
number of cells that stained with PI by the total number of events.
Because scFv-C4-PEST decreased the MFI of GFP, gating for GFP
positive cells and PI-positive cells for viability was not possible.
Statistical analysis
All values represent the mean of at least three independent
experiments, with multiple individual values per experiment.
Statistical significance was determined by one-way ANOVA using
Minitab or Statview statistical software. P values,0.05 were
designated as statistically significant.
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